Table 2 Baseline characteristics (treated set; n = 7034)

Age (years), mean (SD)

63.1 (8.6)

≥ 75 years of age, n (%)

652 (9)

Male, n (%)

5026 (72)

Race, n (%)

 White

5089 (72)

 Asian

1518 (22)

 Black/African American

357 (5)

 Other*

70 (1)

Ethnicity, n (%)

 Hispanic or Latino

1268 (18)

Smoking history, n (%) Current/Ex-smoker

930 (13)/3216 (46)

Time since diagnosis, n (%)

 ≤5 years

1265 (18)

 >5-10 years

1754 (25)

 >10 years

4015 (57)

Region, n (%)

 Europe

2885 (41)

 North America/Australia/New Zealand

1408 (20)

 Latin America

1081 (15)

 Africa

313 (4)

 Asia

1347 (19)

  Northeast Asia

586 (8)

  South/South-East Asia

761 (11)

CV risk factors, any of the below, n (%)

6978 (99)

 History of MI

3275 (47)

 Single-vessel CAD

743 (11)

 Multi-vessel CAD

3285(47)

 CABG

1738(25)

 History of stroke

1631 (23)

 Peripheral occlusive arterial disease

1449 (21)

Glucose-lowering therapy at baseline, n (%)

 None

128 (2)

 Monotherapy

2055 (29)

  Metformin (% of monotherapy)

745 (36)

  Insulin (% of monotherapy)

954 (46)

 Dual therapy

3188 (45)

  Metformin + sulfonylurea (% of dual therapy)

1383 (43)

  Metformin + insulin (% of dual therapy)

1420 (45)

Other therapies (n, %)

  Acetylsalicylic acid

5990 (85)

  Statins

5387 (77)

  Fibrates

630 (9)

 Any antihypertensive therapy (n, %)

6641 (94)

  Blockers of the renin-angiotensin system

5651 (80)

  Beta-blockers

4537 (64)

  Calcium channel blockers

2114 (30)